Recombinant PTH: A study of the outcome of teriparatide therapy for 138 patients with Osteoporosis

Ulster Medical Journal

Volumn 82, Issue 2, 2013, Pages 89-93

  McNeilly, Thomas ^a   McNally, Colette ^a   Finch, Michael ^a   Beringer, Timothy ^a  

^a MUSGRAVE PARK HOSPITAL   (United Kingdom)

Author keywords

Bone Density; Bone Turnover Markers; Osteoporosis; Outcome; Teriparatide

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; RECOMBINANT PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FEMUR NECK; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PATIENT SELECTION; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERTEBRA; VISUAL ANALOG SCALE;

BONE DENSITY; BONE TURNOVER MARKERS; OSTEOPOROSIS; OUTCOME; TERIPARATIDE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TERIPARATIDE;

EID: 84879452629     PISSN: 00416193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in ostmenopausal women. NICE Technology Appraisal Guidance 161. London: NICE; 2008. Available from: http://www.nice.org.uk/nicemedia/live/11748/42508/42508.pdf. Last accessed March 2013.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006:17(12); 1726-33
3. National Osteoporosis Society. Promoting fragile bones: a strategy to reduce the impact of osteoporosis and fragility fractures in England. Bath, England: National Osteoporosis Society; 2009. Available from: http://www.nos.org.uk/document.doc?id=491. Last accessed March 2013.
4. World Health Organization. WHO Scientific Group on the assessment of osteoporosis at Primary Health Care Level. Summary meeting report. Brussels, Belgium, 5-7 May 2004. Geneva: WHO; 2007. Available from: http://www.who.int/chp/topics/Osteoporosis.pdf.
5. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K. Osteoporosis: an age-related and gender-specific disease--a mini-review. Gerontology. 2009: 55(1); 3-12
6. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165(15):1762-8.
7. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. The effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Min Res. 2007: 22(1); 149-57
8. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001:344(19); 1434-41
9. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, EUROFORS Investigators, et al. Effects of two years of daily teriparatide treatment on BMD in post-menopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Mineral Res. 2008: 23(10); 1591-1600
10. Audran MJY. A review of the clinical management and treatment of male patients with osteoporosis. Presented at Eular, Barcelona 2007. Annals of the Rheumatic Disease 2008: 67(suppl II); 26
11. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998: 8(5); 468-89.
12. Mazess RB, Barden H. Bone density of the spine and femur in adult white females. Calcif Tissue Int. 1999: 65(2); 91-9.
13. QDR 1000. Operators Manual. Bedford, MA: Hologic The Women's Health Company; 1989.
14. Roche Diagnostics GmbH, Mannheim, Germany: F. Hoffmann-La Roche Ltd; 2012.
15. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001:33(5);337-43
16. de Boer AG, van Lanschot JJ, Stalmeier PF, van Sandick JW, Hulscher JB, de Haes JC, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res. 2004: 13(2); 311-20
17. Avery, L. Mann-Whitney U Test: equivalent to the Wilcoxon rank sum test. Richmond, VA: Virginia Commonwealth University; 2012. Available from: http://elegans.som.vcu.edu/~leon/stats/utest.html
18. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metabol. 2006: 91(4) 1370-5
19. Miyauchi A. [Monitoring bone turnover markers during treatment with anabolic agent Teriparatide: in particular, treatment using daily and weekly subucutaneous injections.] Clin Calcium. 2012: 22(3); 387-98. Japanese.
20. Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009: 45 (6); 1053-8
21. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007: 18(8); 1023-31